drugset / Trial / NCT05022693
PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
NaSingle-groupOpen-labelOther
Summary
This is an open-label, single-dose study to evaluate the PK profile of the liquid SC formulation of BIO89-100 in approximately 8 male and female subjects with NASH with compensated cirrhosis.
Timeline
- Start
- 2021-08-16
- Primary completion
- 2021-12-21
- Completion
- 2021-12-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegozafermin | Protein / enzyme biologic | 30 mg | Subcutaneous |